<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences

Find me on:

Recent Posts

Behavior-based Preclinical Nerve Injury Model Findings

Posted by MD Biosciences on Aug 24, 2011 3:00:00 PM

We get a lot of questions on the various neuropathic pain models and how to choose the one that's most appropriate or a comparison of what's involved with each model (e.g. surgery, behaviors, centralization, peripheral vs central involvement etc). We thought it may be helpful to discuss the various aspects of these models to assist with the selection and understanding of the mechanisms and behaviors. Of course, it ultimately depends on the drug target and the pathway involved and we can certainly discuss individual specifics with you.

Read More

Topics: Pain

eBook: Pain & Inflammation Linkage | Targets in Overlap

Posted by MD Biosciences on Jul 19, 2011 12:34:00 PM

Neuropathic pain presents a wide variety of challenges to researchers, not the least of which is the simple fact that neuropathic pain, by definition, requires neuronal damage, which in turn automatically initiates immune response that often inflicts further neuronal damage. The interactions between the nervous system and immune system in the case of neuropathic pain make for a very complex story that is only beginning to unfold:

Read More

Topics: Pain, Inflammation

Wisely Choose Preclinical Model: Large vs. Small Species

Posted by MD Biosciences on Jun 8, 2011 9:46:00 AM

Common models for preclinical efficacy often use rodents as they are readily available, cost effective, easy to handle and most familiar to investigators. In choosing a preclinical model, one also needs to consider the anatomical/functional similarity to humans and there are cases where moving onto a larger species is more relevant to the clinic and human condition. Two of those cases are described below:

Read More

Topics: CRO/outsourcing

Neuropathic Pain | Receptor & Receptor Ion Channels

Posted by MD Biosciences on Jun 7, 2011 9:58:00 AM

This post continues on our discussion of potential inflammation-related drug targets for the treatment of neuropathic pain. See also Pro-inflammatory cytokines and anti-inflammatory cytokines as targets in neuropathic pain.

Read More

Topics: Pain

Choosing DNCB or FITC-induced Contact Hypersensitivity Models

Posted by MD Biosciences on Jun 1, 2011 9:37:00 AM

Read More

Topics: Dermal, Inflammation

Cardiovascular Disease & Underlying Inflammatory Events

Posted by MD Biosciences on May 10, 2011 2:51:00 PM

Cardiovascular disease (CVD) including heart disease, vascular disease and atherosclerosis are the most critical global health threats.

An estimated 26 million people are living with the effects of heart disease and is a major cause of death in western society. Until recently the widely held belief was that the CVD is simply the process as a build up of fat on the surface of artery walls. Eventually, this build up of fat blocks the artery and a heart attack or stroke occurs. However, the process has now been identified as a disease of the inner artery wall (intima) and inflammation is a key factor in its progression.

Read More

Topics: Inflammation, Cardiovascular

Inflammation & Pain Processing: Customizable Preclinical Models

Posted by MD Biosciences on May 4, 2011 1:46:00 PM


Chronic, destructive inflammation is at the core of a wide variety of diseases and conditions.

Inflammation, whether acute or chronic, is very often associated with pain. Similar to inflammation, pain can be physiological (an adaptive means of protecting tissues from real or perceived danger) or pathological (chronic, and often debilitating despite resolution of the original stimulus). Chronic pain can be caused by a variety of situations including inflammatory diseases such as osteo‐ and rheumatoid arthritis (inflammatory pain), tumor formation (cancer pain), and nerve injury (neuropathic pain).

Read More

Topics: Pain, Inflammation

Link Between TH17 & Osteoclast Function in RA

Posted by MD Biosciences on Apr 19, 2011 11:33:00 AM

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that affects approximately 1% of the population, and in 2010 cost the US alone $39.2 billion (1,2).  The disease is characterized by bone erosion, cartilage damage, synovial hyperplasia and cellular infiltration, all of which result in debilitating joint pain and stiffness (1,3,4).  Studying preclinical models such as the collagen-induced arthritis (CIA) model and the anti-collagen antibody induced arthritis (ACAIA) model, which show the above hallmarks of disease has allowed the identification of the cells and cytokines involved in the pathogenesis of the disease (5,6).
Read More

Topics: Inflammation

Anti-inflammatory Cytokines | Potential Targets In Neuropathic Pain

Posted by MD Biosciences on Apr 15, 2011 9:29:00 AM

We are continuing our series on the immune system, inflammation related factors and potential drup targets that fall in the overlap of the immune and nervous system. Our last discussion covered the pro-inflammatory cytokines and their relevance to neuropathic pain. This week we will cover anti-inflammatory cytokines.

Read More

Topics: Pain, Inflammation

Adipose Tissue - A Site of Inflammation?

Posted by MD Biosciences on Apr 12, 2011 11:41:00 AM

Inflammatory events associated with Obesity

Read More

Topics: Inflammation